• Both the original formulation containing Arachis oil and the revised formulation without Arachis oil will be in circulation in the supply chain until November 2025.

• Extra care regarding patient allergy to either peanut or soya must be taken when prescribing and dispensing Naseptin Nasal Cream during this transition period. The prescriber/dispenser must be aware of the allergy status of each patient and ensure the formulation patients receive is appropriate.

• The labelling on the original formulation packaging contains a peanut oil boxed warning, the new formulation packaging does not.

For further information, please contact the Medical Information department at Alliance Pharmaceuticals Ltd: call +44 (0)1249 466 966 or email [email protected].